
|Articles|April 27, 2004
VIM Trial results favor PDT for small, subfoveal minimally classic,AMD-related CNV
Verteporfin (Visudyne) photodynamic therapy (PDT) using either a reducedor standard light fluence rate appears to be beneficial for patients withrelatively small, subfoveal minimally classic CNV associated with age-relatedmacular degeneration (AMD), said Philip J. Rosenfeld, MD.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Laru-zova meets primary endpoint in pivotal VISTA trial for X-linked retinitis pigmentosa
2
The importance of treating EBMD before cataract surgery
3
How screen time and eyelid health affect dry eye risk
4
ESCRS 2026: Why surgeons should be willing to use what they prescribe to patients
5











